Webinar: Break the CFDA Code - China Drug Regulations
The discussion, led by Drita Dhami, Director of Operations at ReGDesk, focuses on China's drug registration process and recent regulatory changes. The session features expert Stephanie Chen, who has extensive experience in regulatory affairs.
Key points include:
Drug Registration Overview: The process involves three main steps: preclinical studies, clinical trials, and evaluation/approval. Historically, drug registration in China has been lengthy, often taking 7 to 15 years.
Regulatory Improvements: The CFDA (China Food and Drug Administration) has implemented policies to streamline the registration process, including allowing marketing authorization holders to separate product and manufacturing licenses.
New Drug Classifications: Recent guidance classifies drugs into categories based on their originality and launch history. This aims to align China’s classification with global standards.
Priority Review: Certain drugs, including those for rare diseases and children's health, now have expedited review processes.
Clinical Trials: Local clinical trials are often necessary for drugs entering China for the first time, although some may rely on international data. CFDA now accepts data from foreign Contract Research Organizations (CROs) registered in China.
Oversight and Compliance: The CFDA conducts stringent audits to ensure compliance with Good Clinical Practices (GCPs), with serious penalties for false data submission.
The session concludes with a Q&A, encouraging participants to engage on these important regulatory topics.